Reagent: vBD3

Catalog Number: 4082

Lot Number:

Provided: 100 µl vaccinia virus lysate from BSC-1 cells, 2 x 10⁹ pfu/ml.

Description: Contains the HIV-1 89.6 gp160 gene under control of the vaccinia virus early/late promoter. The 89.6 env gene was cloned into pSC59 and then introduced into vaccinia virus strain WR by homologous recombination.

Special Characteristics: Cells infected with vBD3 express env glycoprotein from the dual-tropic HIV-1 primary isolate 89.6, which uses both CXCR4 and CCR5, as well as a number of other chemokine co-receptors for entry. The gp160 is expressed on the surface of infected cells, and supports cell-cell fusion with CD4+ cells. Can also be used to generate gp120 from supernatants of infected cells. Sterility: Negative for bacteria, fungi, and mycoplasma.

Recommended Storage: -70degreeC.

Contributor: Dr. Ronald Collman and Dr. Robert Doms.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: vBD3 from Dr. Ronald Collman and Dr. Robert Doms." Also include the references cited above in any publications.

The US Government has submitted a patent application on the parent plasmid pSC59.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Sally Hu at the NIH Office of Technology Transfer, Email: hus@mail.nih.gov, Phone: 301-435-5606, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated: June 24, 2013